Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
This makes essential nutrient delivery harder
on a two-year, National Institutes of Health (NIH)-funded Phase II study to investigate and validate the use of small peptides that target the visceral pain in irritable bowel syndrome (IBS)
What were the findings of the LEADER trial and their implications for patients with type II diabetes and high cardiovascular risk
I have been reading about GLP-1 receptor agonists and I think they might be a good addition to my current approach
US$ 26.22
US$ 25.41
US$ 28.76
US$ 23.18
US$ 28.70
